Galmed Pharmaceuticals Ltd.
GLMD
$4.63
$0.8121.05%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.63M | 3.69M | 3.64M | 3.26M | 3.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.96M | 9.29M | 8.51M | 7.11M | 7.03M |
| Operating Income | -9.96M | -9.29M | -8.51M | -7.11M | -7.03M |
| Income Before Tax | -11.34M | -11.12M | -10.31M | -8.70M | -8.72M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.34 | -11.12 | -10.31 | -8.70 | -8.72 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.34M | -11.12M | -10.31M | -8.70M | -8.72M |
| EBIT | -9.96M | -9.29M | -8.51M | -7.11M | -7.03M |
| EBITDA | -5.10M | -7.18M | -8.43M | -7.05M | -6.99M |
| EPS Basic | -14.36 | -16.55 | -19.20 | -28.76 | -44.45 |
| Normalized Basic EPS | -7.29 | -8.00 | -9.65 | -13.72 | -23.52 |
| EPS Diluted | -14.36 | -16.55 | -19.20 | -28.76 | -44.45 |
| Normalized Diluted EPS | -7.29 | -8.00 | -9.65 | -13.72 | -23.52 |
| Average Basic Shares Outstanding | 3.21M | 2.75M | 2.15M | 1.60M | 1.02M |
| Average Diluted Shares Outstanding | 3.21M | 2.75M | 2.15M | 1.60M | 1.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |